Baseline characteristics of the individual case safety reports concerning immune checkpoint inhibitor-related haemophagocytic lymphohistiocytosis

CharacteristicPatients No. (%) (n = 38)
Age
 Reported33 (87)
  Median [IQR], years63 [45–72]
 Not reported5 (13)
Sex
 Male29 (76)
 Female9 (24)
Cancer type
 Melanoma21 (55)
 Lung cancer5 (13)
 Bladder cancer3 (8)
 Renal cell carcinoma2 (5)
 Hodgkin disease1 (3)
 Transitional cell carcinoma1 (3)
 Adenocarcinoma gastric1 (3)
 Thymoma1 (3)
 T cell lymphoblastic leukemia acute1 (3)
 Not reported2 (5)
Co-suspected drugs
 Reported4 (10)
  Antineoplastic agents2 (5)
  Antibacterial agents2 (5)
 Not reported34 (90)
Drugs
 Anti-CTLA-4 (ipilimumab) monotherapy7 (18)
 Anti-PD-1 monotherapy
  nivolumab14 (37)
  pembrolizumab7 (18)
 Anti-PD-L1 monotherapy
  Atezolizumab1 (3)
 ipilimumab and nivolumab combination therapy5 (13)
 nivolumab and ipilimumab sequential therapy3 (8)
 pembrolizumab and ipilimumab sequential therapy1 (3)
Reporting
 20141 (3)
 20153 (8)
 20166 (16)
 201710 (26)
 201818 (47)

Abbreviations: IQR interquartile range, CTLA-4 Cytotoxic T-Lymphocyte Antigen 4, PD-1 Programmed cell Death protein 1, PD-L1 Programmed cell Death-Ligand 1